论文部分内容阅读
已证实,相当部分乳癌的细胞具有雌激素受体蛋白(Estraphilin),其生长依赖雌激素的支持,卵巢切除,乳癌生长减慢或退缩,据此,相应的抗雌激素药物能用于乳癌的治疗。三苯氧胺(他莫昔芬,Tamoxifen)和氨基导眠能(氨苯哌啶酮,Aminoglutethimide,AG)是我国近几年先后生产的抗雌激素药物。由于这二种药均用于晚期乳腺癌,临床使用时偶有忽视各自的作用特点,在一定程度上影响了抗癌效果。三苯氧胺作用机理为与雌二醇竞争乳癌细胞的雌激素受体,阻止雌激素对乳癌的促进作用,抑制乳癌的生长。氨基导眠能则为阻滞胆固醇的侧链裂解转变为孕烯醇酮,同时又是强有力的芳香化酶抑制剂,致使血浆和
It has been demonstrated that a substantial fraction of breast cancer cells have Estraphilin whose growth is dependent on estrogen support, ovariectomy, slowing or shrinking breast cancer growth, whereby the corresponding antiestrogen can be used in breast cancer treatment. Tamoxifen (Tamoxifen) and Aminoglutethimide (AG) are antiestrogens that have been produced in China in recent years. As these two drugs are used for advanced breast cancer, occasionally neglected their clinical role in the role of the two, to a certain extent, affect the anti-cancer effect. The mechanism of action of tamoxifen is to compete with estradiol for the estrogen receptor of breast cancer cells to prevent the promotion of estrogen on breast cancer and inhibit the growth of breast cancer. Aminopramine can then block the side chain cleavage of cholesterol into pregnenolone, but also a powerful aromatase inhibitor, resulting in plasma and